Budget Impact of Introducing Accuchek® Smartguide Real-Time Continuous Glucose Monitoring (RtCGM) Solution for Diabetes Management in Portugal
Author(s)
Joana Torres, MSc1, Osvaldo Ulises Garay, MSc2, Anamaria V. Olivieri, MSc3, Manisha Panchal, MA4, Paco Cerletti, PhD2, Filipa Ramilo-Gomes, PharmD, MSc1.
1Roche Sistemas de Diagnósticos, Amadora, Portugal, 2Roche Diagnostics International, Rotkreuz, Switzerland, 3IQVIA, Basel, Switzerland, 4IQVIA, Gurugram, India.
1Roche Sistemas de Diagnósticos, Amadora, Portugal, 2Roche Diagnostics International, Rotkreuz, Switzerland, 3IQVIA, Basel, Switzerland, 4IQVIA, Gurugram, India.
OBJECTIVES: To estimate the 5-year budget impact of introducing Accu-Chek® SmartGuide, a novel real-time Continuous Glucose Monitoring (rtCGM) solution with predictive features. The analysis was tailored to adults with Type 1 (T1D) and Type 2 Diabetes (T2D) on multiple daily insulin injections (MDI) in Portugal, from a healthcare payer perspective.
METHODS: A budget impact model was developed comparing two scenarios: "World without Accu-Chek® SmartGuide" and "World with Accu-Chek® SmartGuide". The model considered 72,034 adults with T1D and 18,296 with T2D, on MDI. Inputs for population, market shares, and unit costs (medication, monitoring, outpatient visits, acute events, chronic complications) were estimated with Portuguese data. Chronic complications were modeled using the IQVIA Core Diabetes Model. Benefit of Accu-Chek® SmartGuide on non-severe hypoglycaemia was based on in-silico study data. Market shares in the base case assumed Accu-Chek® SmartGuide uptake from other CGMs and a scenario analysis explored an increased CGM uptake from self-monitoring of blood glucose (SMBG).
RESULTS: In the base case, introducing Accu-Chek® SmartGuide for people with T1D and T2D on MDI resulted in a 5-year net budget impact of €-6.97 million (approximately €-77.13 per patient). Savings were primarily driven by reduced acute events and chronic complications costs. In the scenario where Accu-Chek® SmartGuide increases CGM uptake from SMBG, the 5-year net impact was €-5.13 million, explained by higher monitoring costs and fewer clinical event costs.
CONCLUSIONS: The introduction of Accu-Chek® SmartGuide in Portugal may lead to budget savings, mainly due to its potential to reduce non-severe hypoglycaemia and other clinical event costs. The results are sensitive to assumptions on projected market share uptakes, and the efficacy data on reducing non-severe hypoglycaemia.
METHODS: A budget impact model was developed comparing two scenarios: "World without Accu-Chek® SmartGuide" and "World with Accu-Chek® SmartGuide". The model considered 72,034 adults with T1D and 18,296 with T2D, on MDI. Inputs for population, market shares, and unit costs (medication, monitoring, outpatient visits, acute events, chronic complications) were estimated with Portuguese data. Chronic complications were modeled using the IQVIA Core Diabetes Model. Benefit of Accu-Chek® SmartGuide on non-severe hypoglycaemia was based on in-silico study data. Market shares in the base case assumed Accu-Chek® SmartGuide uptake from other CGMs and a scenario analysis explored an increased CGM uptake from self-monitoring of blood glucose (SMBG).
RESULTS: In the base case, introducing Accu-Chek® SmartGuide for people with T1D and T2D on MDI resulted in a 5-year net budget impact of €-6.97 million (approximately €-77.13 per patient). Savings were primarily driven by reduced acute events and chronic complications costs. In the scenario where Accu-Chek® SmartGuide increases CGM uptake from SMBG, the 5-year net impact was €-5.13 million, explained by higher monitoring costs and fewer clinical event costs.
CONCLUSIONS: The introduction of Accu-Chek® SmartGuide in Portugal may lead to budget savings, mainly due to its potential to reduce non-severe hypoglycaemia and other clinical event costs. The results are sensitive to assumptions on projected market share uptakes, and the efficacy data on reducing non-severe hypoglycaemia.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE108
Topic
Economic Evaluation, Medical Technologies
Topic Subcategory
Budget Impact Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)